[Skip to Content]
[Skip to Content Landing]
January 1967

Methotrexate for Psoriasis

Author Affiliations


From the Division of Dermatology, Department of Medicine, University of California School of Medicine, San Francisco, (Drs. Rees, Bennett, and Maibach) and the Department of Dermatology, Straub Clinic, Honolulu (Dr. Arnold).

Arch Dermatol. 1967;95(1):2-11. doi:10.1001/archderm.1967.01600310008002

Methotrexate is used for psoriasis by the majority of teaching services of dermatology in the United States. Three modes of administration were compared: small daily doses by mouth in interrupted schedules, single large weekly oral doses, and parenteral doses. All methods were effective and had toxicity, but the parenteral route showed the greatest toxicity. The drug is contraindicated in pregnancy, hematological disorders, peptic ulceration, and liver disease. Chromosomal breaks have been reported with greater frequency than normal. Renal clearance is vital. The drug should be considered only for very severe forms of psoriasis.